Reference
Ribaldone DG, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: An observational study. Revista Espanola de Enfermedades Digestivas 112: 195-200, No. 3, 2020. Available from: URL: http://doi.org/10.17235/REED.2020.6693/2019
Rights and permissions
About this article
Cite this article
Adalimumab. Reactions Weekly 1823, 22 (2020). https://doi.org/10.1007/s40278-020-83650-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-83650-8